Indaptus Therapeutics, Inc.

INDP

NASDAQ

Healthcare

Biotechnology

New York City, NY, US7 employeesindaptusrx.com

$1.57

-0.13(-7.35%)

Mkt Cap $3M

$1.55

$14.28

52-Week Range

At a Glance

AI-generated

8-K

Indaptus Therapeutics announced the resignation of CFO Nir Sassi and appointed Qinglai Lu to the Board and Audit Committee and Yu Ding as CFO, effective in early April 2026.

$3M

Market Cap

—

Revenue

-$17M

Net Income

Employees7

Fundamentals

How The Business Makes Money

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Industry Biotechnology

Activity

What Changed Recently

Management Change

Apr 2, 2026

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** ** Resign

Management Change

Jan 19, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously

Management Change

Jan 7, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 8,

Securities Modification

Feb 26, 2026

. Material Modification to Rights of Security Holders. As described below under Item 5.07 of this Current Report on Form 8-K, at the Special Meeting, stockholde

Material Agreement

Feb 11, 2026

Entry into a Material Definitive Agreement. On February 11, 2026, Indaptus Therapeutics, Inc. (the “Company”) entered into warrant repricing agreements (the “Re

Peer Companies

Company	Price	Change	Market Cap	P/E
SLRXSLRX	$0.84	+29.23%	$5M	—
GTBPGT Biopharma, Inc.	$0.44	+7.01%	$5M	-0.1
AZTRAzitra, Inc.	$0.23	-4.21%	$2M	—
REVBRevelation Biosciences, I...	$1.22	-0.80%	$2M	-0.8
PTIXProtagenic Therapeutics, ...	$0.53	+1.92%	$1M	-0.3
LIPOLipella Pharmaceuticals I...	$0.16	-8.00%	$744.0K	-0.1
SLXNSilexion Therapeutics Ltd...	$1.18	-3.28%	$661.9K	-0.3
ATXIAvenue Therapeutics, Inc.	$0.16	-40.72%	$523.7K	-0.2

Analyst View

Company Profile

CIK0001857044

ISINUS45339J2042

CUSIP45339J204

Phone347 480 9760

Address3 Columbus Circle, New York City, NY, 10019, US

SEC EDGAR